131 related articles for article (PubMed ID: 2144020)
1. Preserving adult height potential in girls with idiopathic true precocious puberty.
Kreiter M; Burstein S; Rosenfield RL; Moll GW; Cara JF; Yousefzadeh DK; Cuttler L; Levitsky LL
J Pediatr; 1990 Sep; 117(3):364-70. PubMed ID: 2144020
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment.
Adan L; Chemaitilly W; Trivin C; Brauner R
Clin Endocrinol (Oxf); 2002 Mar; 56(3):297-302. PubMed ID: 11940040
[TBL] [Abstract][Full Text] [Related]
3. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
Cara JF; Kreiter ML; Rosenfield RL
J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
[TBL] [Abstract][Full Text] [Related]
4. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
Léger J; Reynaud R; Czernichow P
J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
[TBL] [Abstract][Full Text] [Related]
5. Adult height in girls with idiopathic true precocious puberty.
Brauner R; Adan L; Malandry F; Zantleifer D
J Clin Endocrinol Metab; 1994 Aug; 79(2):415-20. PubMed ID: 8045957
[TBL] [Abstract][Full Text] [Related]
6. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
7. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
8. Adult height in advanced puberty with or without gonadotropin hormone releasing hormone analog treatment.
Couto-Silva AC; Adan L; Trivin C; Brauner R
J Pediatr Endocrinol Metab; 2002 Mar; 15(3):297-305. PubMed ID: 11924932
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
[TBL] [Abstract][Full Text] [Related]
10. Precocious puberty: auxological criteria discriminating different forms.
Bassi F; Bartolini O; Neri AS; Gheri RG; Bucciantini S; Cheli D; Bruni V
J Endocrinol Invest; 1994 Nov; 17(10):793-7. PubMed ID: 7699213
[TBL] [Abstract][Full Text] [Related]
11. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
12. Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty.
Lin TH; LePage ME; Henzl M; Kirkland JL
J Pediatr; 1986 Dec; 109(6):954-8. PubMed ID: 2946840
[TBL] [Abstract][Full Text] [Related]
13. Final height in girls with slowly progressive untreated central precocious puberty.
Ghirri P; Bottone U; Gasperi M; Bernardini M; Coccoli L; Giovanelli R; Boldrini A
Gynecol Endocrinol; 1997 Oct; 11(5):301-5. PubMed ID: 9385528
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty.
Brauner R; Malandry F; Rappaport R
Eur J Pediatr; 1992 Oct; 151(10):728-30. PubMed ID: 1425790
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
16. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.
Rosenfield RL; Garibaldi LR; Moll GW; Watson AC; Burstein S
J Clin Endocrinol Metab; 1986 Dec; 63(6):1386-9. PubMed ID: 2946712
[TBL] [Abstract][Full Text] [Related]
17. [Improvement of expected and final height in girls with central precocious puberty treated with gonadotropin releasing hormone analogues].
Gómez F; Picó AM; Vargas F; Mauri M
Med Clin (Barc); 1996 Nov; 107(18):681-4. PubMed ID: 9082075
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of long-acting luteinizing-hormone-releasing hormone agonist in central precocious puberty.
Swaenepoel C; Chaussain JL; Roger M
Horm Res; 1991; 36(3-4):126-30. PubMed ID: 1840142
[TBL] [Abstract][Full Text] [Related]
19. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
20. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty].
Chen SK; Fan X; Tang Q
Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
